Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors.
Animals
Antineoplastic Agents
/ pharmacology
COS Cells
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Chlorocebus aethiops
Drug Resistance, Neoplasm
/ drug effects
ErbB Receptors
/ antagonists & inhibitors
Humans
Lung Neoplasms
/ drug therapy
Lysosomes
/ drug effects
Mice
Mice, Transgenic
Microtubules
/ drug effects
Protein Kinase Inhibitors
/ pharmacology
EGFR mutants
NSCLC
chloroquine
microtubule dysfunction
tyrosine kinase inhibitors
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
07
2019
accepted:
24
11
2019
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
15
5
2021
Statut:
epublish
Résumé
Oncogene-addicted cancers are predominantly driven by specific oncogenic pathways and display initial exquisite sensitivity to designer therapies, but eventually become refractory to treatments. Clear understanding of lung tumorigenic mechanisms is essential for improved therapies.
Identifiants
pubmed: 32194831
doi: 10.7150/thno.38729
pii: thnov10p2727
pmc: PMC7052910
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2727-2743Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL131477
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197697
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Oncogene. 2004 May 13;23(22):3999-4006
pubmed: 15007386
FEBS Lett. 2001 Feb 16;490(3):142-52
pubmed: 11223029
Theranostics. 2019 Sep 23;9(24):7122-7139
pubmed: 31695757
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Cell Cycle. 2006 Mar;5(6):599-602
pubmed: 16582613
Surg Neurol. 2007 Apr;67(4):388-91
pubmed: 17350410
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Cancer Res. 2006 Jan 1;66(1):283-9
pubmed: 16397241
Biochim Biophys Acta. 1983 Dec 19;763(4):368-76
pubmed: 6652115
J Clin Invest. 2008 Jan;118(1):79-88
pubmed: 18097482
Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):441-67
pubmed: 15982921
Am J Epidemiol. 1989 Apr;129(4):740-52
pubmed: 2923122
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Ann Intern Med. 2006 Mar 7;144(5):337-43
pubmed: 16520474
Exp Cell Res. 1979 Aug;122(1):159-67
pubmed: 477753
Am J Physiol Cell Physiol. 2002 Mar;282(3):C420-33
pubmed: 11832327
Science. 2002 Jul 5;297(5578):63-4
pubmed: 12098689
Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a016949
pubmed: 24296170
Exp Cell Res. 2009 Feb 15;315(4):683-96
pubmed: 19278030
Exp Cell Res. 1980 Nov;130(1):127-35
pubmed: 7192635
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7681-6
pubmed: 18505839
J Biol Chem. 2004 Oct 8;279(41):43254-60
pubmed: 15292251
Clin Cancer Res. 2008 Apr 15;14(8):2285-94
pubmed: 18413817
J Clin Oncol. 2005 Sep 1;23(25):5900-9
pubmed: 16043828
J Cell Biol. 1987 Sep;105(3):1253-65
pubmed: 3308906
Eur J Cell Biol. 1989 Apr;48(2):250-63
pubmed: 2743999
Science. 1994 Feb 4;263(5147):684-7
pubmed: 8303278
Nat Protoc. 2012 Jan 05;7(1):128-42
pubmed: 22222788
Theranostics. 2019 Aug 14;9(21):6157-6174
pubmed: 31534543
ESMO Open. 2016 May 11;1(3):e000060
pubmed: 27843613
Toxicol Rep. 2014 Nov 04;1:963-968
pubmed: 28962308
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10166-10173
pubmed: 16801540
Mol Cancer Ther. 2004 Apr;3(4):465-72
pubmed: 15078990
Science. 2004 Aug 20;305(5687):1163-7
pubmed: 15284455
Theranostics. 2016 May 24;6(8):1232-43
pubmed: 27279914
J Biol Chem. 1994 Jun 3;269(22):15749-55
pubmed: 8195228
Oncogene. 2001 May 17;20(22):2761-70
pubmed: 11420688
Mol Cell Biol. 2007 Jan;27(1):267-82
pubmed: 17060458
J Cell Physiol. 2000 Oct;185(1):47-60
pubmed: 10942518
Eur J Cell Biol. 2001 Apr;80(4):285-94
pubmed: 11370743
Mol Biol Cell. 2001 Jun;12(6):1897-910
pubmed: 11408594
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7026-30
pubmed: 1353884
Br J Cancer. 2017 Feb 28;116(5):568-574
pubmed: 28103612
Cancer Res. 2006 Jul 15;66(14):6990-7
pubmed: 16849543
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29449326
Adv Drug Deliv Rev. 2003 Nov 14;55(11):1405-19
pubmed: 14597138
J Cell Biol. 1984 Feb;98(2):375-81
pubmed: 6319424
J Biol Chem. 1996 Nov 29;271(48):30340-6
pubmed: 8939994
Cancer Cell. 2003 Jun;3(6):519-23
pubmed: 12842080
Nat Rev Cancer. 2008 Nov;8(11):835-50
pubmed: 18948996
Hoppe Seylers Z Physiol Chem. 1981 May;362(5):549-56
pubmed: 6166527
Nature. 1987 Aug 27-Sep 2;328(6133):820-3
pubmed: 3498122
Nat Rev Mol Cell Biol. 2009 Sep;10(9):609-22
pubmed: 19696798
Cancer Discov. 2015 Aug;5(8):850-9
pubmed: 25971938
Theranostics. 2018 Feb 12;8(7):1808-1823
pubmed: 29556358
Histochem Cell Biol. 2008 May;129(5):563-78
pubmed: 18288481
Biochim Biophys Acta. 1978 Jul 3;541(3):372-84
pubmed: 78729
Cancer Sci. 2008 Jul;99(7):1293-303
pubmed: 18429951
J Cell Biol. 1984 Sep;99(3):1092-100
pubmed: 6381504